Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics.
We compared symptom severity and quality of life (QOL) in schizophrenic patients adequately treated with typical antipsychotics (TAP) or clozapine (CZP). Groups did not differ in symptom severity or QOL. Clozapine caused fewer extrapyramidal symptoms. Negative and extrapyramidal symptoms predicted QOL. Similar outcome in both groups suggests a common ceiling to antipsychotic efficacy.
Strejilevich
Sergio A
SA
Servicio de Psicopatología, Hospital General de Agudos Parmenio Piñero, Av. Varela 1301, Buenos Aires, Argentina.
Palatnik
Ana
A
Avila
Rubén
R
Bustin
Julián
J
Cassone
Julieta
J
Figueroa
Soledad
S
Gimenez
Mariana
M
de Erausquin
Gabriel A
GA
D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000453:epidemiology; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003024:Clozapine